Cara Therapeutics Inc

CARA30 Nov 2024
Healthcare
$0.29
+0.06 (+5.52%)
Lowest Today
$0.29
Highest Today
$0.31
Today’s Open
$0.29
Prev. Close
$0.29
52 Week High
$1.31
52 Week Low
$0.24
To Invest in Cara Therapeutics Inc

Cara Therapeutics Inc

Healthcare
CARA30 Nov 2024
+0.06 (+5.52%)
1M
3M
6M
1Y
5Y
Low
$0.29
Day’s Range
High
$0.31
0.29
52 Week Low
$0.24
52-Week Range
52 Week High
$1.31
0.24
1 Day
-
1 Week
-4.26%
1 month return
+0.58%
3 month return
-18.84%
6 month return
-51.33%
1 Year return
-69.82%
3 Years return
-97.78%
5 Years return
-98.87%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
4.1
Chescapmanager LLC
3.1
Farallon Capital Management, L.L.C.
2.84
Vanguard Total Stock Mkt Idx Inv
2.47
Disciplined Growth Investors Inc
2.03
Renaissance Technologies Corp
2.02
BNP Paribas Arbitrage, SA
1.96

Market Status

Fundamentals
Market Cap
15.8 mln
PB Ratio
22.35
PE Ratio
0
Enterprise Value
-22.82 mln
Total Assets
125.84 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Organisation
Cara Therapeutics Inc
Employees
55
Industry
Biotechnology
CEO
Mr. Christopher A. Posner
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities